A pioneering approach to biotherapeutic antibody discovery

Immunotherapy has revolutionized cancer treatment, yet the drug discovery process to develop new biotherapeutic antibodies remains arduous.

By Kimberley Bryon-Dodd, PhD • Aug. 7, 2023

Is the COVID-19 market crashing?

Pfizer’s recent earnings report could foretell major trouble in the market for pandemic products.

By Meagan Parrish • Aug. 3, 2023

Explore the Trendline➔

Commercialization, marketing and social media

As the pharma industry stares down a historic patent cliff, macroeconomic headwinds and challenging R&D costs for increasingly complex medicines, nailing the launch of new medicines has become increasingly critical. 

By PharmaVoice staff

New Alzheimer’s treatments are the tip of the iceberg in a long-stymied area of medicine

A smaller player in the Alzheimer’s space, Prothena is approaching the next phase of treatments, including prevention and clinical trial evolution.

By Michael Gibney • Aug. 3, 2023

How CymaBay overcame a NASH failure for another shot at liver disease success

The biotech’s 2019 trial halt was a major disappointment in NASH, but a turnaround has shown late-stage potential in another liver disease with unmet needs.

By Michael Gibney • Aug. 2, 2023

Biosimilar makers split strategies in bid to take on top-selling Humira

In challenging AbbVie for share of a $19 billion drug market, competitors are testing whether high upfront discounts or behind-the-scenes rebates can win them an advantage.

By Jonathan Gardner • July 26, 2023

Biogen’s layoffs are the latest in an industrywide slip

Over 100 biotech companies so far this year have cut staff due to persistent funding challenges.

By Karissa Waddick • July 26, 2023

In fast-growing KRAS field, this oncology veteran is chasing the toughest cancer targets

Loïc Vincent, chief scientific officer at Affini-T, explains the company’s T cell approach and latest moves toward the clinic.

By Alexandra Pecci • July 25, 2023

A leading CRO’s chief exec on why a ‘brave new world’ of clinical research is here

Peter Benton, co-CEO of Worldwide Clinical Trials, explains how the rise of the mid-sized pharma company has changed drug R&D.  

By Taren Grom and Meagan Parrish • July 20, 2023

Google for genes? This AI company aims to curate the entire human genome.

Genomenon’s acquisition of their contract scientific partner Boston Genetics will help them unlock the potential of genetic knowledge. 

By Michael Gibney • July 20, 2023

As biologics boom, here’s how manufacturers are keeping up

Stevanato’s focus on biologic-related vials and delivery devices has put it in a unique position amid a quickly growing market.

By Michael Gibney • July 19, 2023

AI’s great expectations

With AI expectations riding high, here’s a look at some areas where the technology could be most useful in drug development. 

By Karissa Waddick • July 19, 2023

What the 2014 Ebola outbreak taught this biotech CEO about persuasion

A former WHO epidemiologist is applying lessons learned during the Ebola epidemic to her work leading a company at the forefront of women’s health: the reproductive microbiome.

By Alexandra Pecci • July 18, 2023

DCTs create fresh privacy challenges for review boards. Now there are guidelines.

A new toolkit developed by industry stakeholders paves the way for faster reviews.

By Kelly Bilodeau • July 17, 2023

FDA’s upcoming psychedelic review looms large for a budding industry

A new psychedelic guidance from the agency gives a clue into how it could analyze drugs in the space, but industry leaders are eager for more.

By Karissa Waddick • July 12, 2023

A rare disease veteran, Inozyme’s new CEO sharpens the company’s focus

After taking the reins from the company’s founding CEO, Douglas Treco is guiding Inozyme through the clinic.

By Alexandra Pecci • July 11, 2023

Merck’s New Jersey campus is getting a biotech makeover

With a purchase of the pharma giant’s Kenilworth campus, Onyx Equities is looking to make the spot a go-to biotech hub.

By Michael Gibney • July 11, 2023

Cancer R&D is shifting — here’s what’s changing most

A report from IQVIA shows China gaining ground in cancer drug R&D, and a growing industry focus on new drug targets.

By Kelly Bilodeau • July 10, 2023

Following FDA’s full approval of Leqembi, here’s what else is in the Alzheimer’s pipeline

Leqembi’s U.S. approval is a milestone in Alzheimer’s research and medicine — and there are a few other late-stage biologic drugs that could follow.

By Michael Gibney • July 7, 2023

Pharma’s strike-from-all-sides attack on the IRA could be decided by the Supreme Court

New lawsuits challenging the Inflation Reduction Act’s price negotiation program hit the government with multiple Constitution-based challenges.

By Alexandra Pecci • July 6, 2023

Women’s healthcare investments are hot. So where are the new menopause drugs?

NK3 receptor antagonists offer a new option, but experts say more are needed.

By Kelly Bilodeau • July 5, 2023

The stories you’ve read the most in 2023 (so far)

From staff shortages to presidential candidates and the M&A outlook, here are our most-read stories from the first half of the year.

By PharmaVoice Staff • July 3, 2023

A pharma summer — how leaders unwind and recharge their teams in the warmer months

Vacation is calling, but so are patients. Here's how the industry adjusts in the summer. 

By Michael Gibney • June 30, 2023

Major clinical trial trends transforming life sciences research

From AI to diversity and decentralized trials, here’s how clinical trial operations are evolving.

By Karissa Waddick • June 29, 2023

Transgender patients are rarely included in clinical trials. Can pharma fix it?

Transgender and nonbinary patients suffer more adverse health outcomes than the general population, yet are often underrepresented in clinical research. Now, there’s momentum to change the status quo.

By Karissa Waddick • June 29, 2023

Pharma is still figuring out how to make DEI work. Here are some of the strategies companies are trying

Although DEI efforts have ramped up, the industry is still searching for proven ways to get results.

By Alexandra Pecci • June 28, 2023